Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis.
Aged
Aged, 80 and over
Comorbidity
Computed Tomography Angiography
Female
Follow-Up Studies
France
/ epidemiology
Giant Cell Arteritis
/ diagnostic imaging
Glucocorticoids
/ therapeutic use
Humans
Male
Middle Aged
Positron Emission Tomography Computed Tomography
Prognosis
Recurrence
Retrospective Studies
Risk Factors
Substance-Related Disorders
/ epidemiology
Takayasu Arteritis
/ diagnostic imaging
Tertiary Care Centers
GIANT CELL ARTERITIS
GLUCOCORTICOID DEPENDENCE
GLUCOCORTICOIDS
LARGE-VESSEL VASCULITIS
RELAPSE
Journal
The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
accepted:
20
02
2019
pubmed:
17
3
2019
medline:
21
5
2021
entrez:
17
3
2019
Statut:
ppublish
Résumé
To identify characteristics and factors associated with relapse and glucocorticoid (GC) dependence in patients with giant cell arteritis (GCA). We retrospectively analyzed 326 consecutive patients with GCA followed for at least 12 months. Factors associated with relapse and GC dependence were identified in multivariable analyses. The 326 patients (73% women) were followed up for 62 (12-262) months. During followup, 171 (52%) patients relapsed, including 113 (35%) who developed GC dependence. Relapsing patients had less history of stroke (p = 0.01) and presented large-vessel vasculitis (LVV) more frequently on imaging (p = 0.01) than patients without relapse. During the first months, therapeutic strategy did not differ among relapsing and nonrelapsing patients. GC-dependent patients were less likely to have a history of stroke (p = 0.004) and presented LVV on imaging more frequently (p = 0.005) than patients without GC-dependent disease. In multivariable analyses, LVV was an independent predictive factor of relapse (HR 1.49, 95% CI 1.002-2.12; p = 0.04) and GC dependence (OR 2.19, 95% CI 1.19-4.05; p = 0.01). Conversely, stroke was a protective factor against relapse (HR 0.21, 95% CI 0.03-0.68; p = 0.005) and GC-dependent disease (OR 0.10, 95% CI 0.001-0.31; p = 0.0005). Patients with a GC-dependent disease who received a GC-sparing agent had a shorter GC treatment duration than those without (p = 0.008). In this study, LVV was an independent predictor of relapse and GC dependence. Further prospective studies are needed to confirm these findings and to determine whether patients with LVV require a different treatment approach.
Identifiants
pubmed: 30877210
pii: jrheum.181127
doi: 10.3899/jrheum.181127
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM